311
Participants
Start Date
September 22, 2020
Primary Completion Date
January 21, 2022
Study Completion Date
February 2, 2022
AK0529
AK0529 capsule will be orally administered at the twice-daily dosing levels of 10 mg, 20 mg, or 40 mg for five days based on the patient's weight.
Matching placebo of AK0529
The placebo capsule was made with the same smell and appearance as AK0529 but without the active ingredients and will be orally administered per the same treatment schedule as those in the experimental arm.
Beijing Children's Hospital, Beijing
Peking University Third Hospital, Beijing
Shengjing Hospital of China Medical University, Shengyang
The First Bethune Hospital of Jilin University, Changchun
Children's Hospital of Shanghai, Shanghai
Shanghai Children's Medical Center, Shanghai
Children's Hospital of Nanjing Medical University, Nanjing
Jiangsu Province Hospital, Nanjing
Wuxi Children's Hospital, Wuxi
Children's Hospital of Soochow University, Suzhou
Liaocheng People's Hospital, Liaocheng
Tianjin Children's Hospital, Tianjin
The Children's Hospital of Zhejiang University School of Medicine, Hangzhou
The Second Affiliated Hospital and Yuying Children's Hospital of WMU, Wenzhou
Jiangxi Provincial Children's Hospital, Nanchang
The First Affiliated Hospital of Xiamen University, Xiamen
Xiamen Maternity and Child Healthcare Hospital, Xiamen
Children's Hospital of Chongqing Medical University, Chongqing
Hunan Provincial People's Hospital, Changsha
Wuhan Children's Hospital, Wuhan
Henan Children's Hospital, Zhengzhou
The Third Affiliated Hospital of Zhengzhou University, Zhengzhou
Guangzhou Women and Children's Medical Center, Guangzhou
Shenzhen Children's Hospital, Shenzhen
Boai Hospital of Zhongshan, Zhongshan
The First Affiliated Hospital of Guangxi Medical University, Nanjing
Hainan Third People's Hospital, Sanya
West China Women's and Children's Hospital, Chengdu
Shanghai Ark Biopharmaceutical Co., Ltd.
INDUSTRY